Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 13:S0735-1097(24)08018-5.
doi: 10.1016/j.jacc.2024.07.032. Online ahead of print.

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease: A Secondary Analysis of DANFLU-1

Katja Vu Bartholdy  1 , Niklas Dyrby Johansen  1 , Kira Hyldekær Janstrup  1 , Daniel Modin  1 , Joshua Nealon  2 , Sandrine Samson  2 , Matthew M Loiacono  3 , Rebecca Harris  4 , Carsten Schade Larsen  5 , Anne Marie Reimer Jensen  1 , Nino Emanuel Landler  1 , Brian L Claggett  5 , Scott D Solomon  6 , Martin J Landray  7 , Gunnar H Gislason  8 , Ditte Hansen  9 , Lars Køber  10 , Pradeesh Sivapalan  11 , Lasse Skafte Vestergaard  12 , Jens Ulrik Stæhr Jensen  11 , Tor Biering-Sørensen  13
Affiliations
Free article

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease: A Secondary Analysis of DANFLU-1

Katja Vu Bartholdy et al. J Am Coll Cardiol. .
Free article
No abstract available

Keywords: chronic kidney disease; influenza; pragmatic; randomized controlled trial; vaccine.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures This study has been supported by Sanofi. Drs Samson, Loiacono, Nealon, and Harris are full-time employees of Sanofi and may own shares and/or stock options in the company. Dr Larsen is chief physician at Danske Lægers Vaccinations Service, part of the European LifeCare Group; and has received speaker fees and served on advisory boards for GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, Takeda, and Valneva. Dr Claggett has received consulting fees from Amgen, Cardurion, Corvia, Myokardia, and Novartis. Dr Solomon has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi, Theracos, and US2.AI; and has received consulting fees from Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Puretech Health. Dr Køber has received speaker fees from Novo Nordisk, Novartis, AstraZeneca, Boehringer Ingelheim, and Bayer. Dr Biering-Sørensen has served as steering committee member of the Amgen-financed GALACTIC-HF trial, the Boehringer Ingelheim–financed SHARP3 trial, and the Boston Scientific–financed LUX-Dx TRENDS trial; has served on advisory boards for Sanofi, GlaxoSmithKline, and Amgen; has received speaker honoraria from Bayer, GlaxoSmithKline, Novartis, Novo Nordisk, and Sanofi; and has received research grants from GE Healthcare, AstraZeneca, Novo Nordisk, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

LinkOut - more resources